Akari Therapeutics Financials - Benzinga

Akari Therapeutics PLC

AKTXNASDAQ

Trade with Public

Trade with Public

$10.05

-0.38-3.64%

Last update: Sep 1, 12:11 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Akari Therapeutics Financials

Akari Therapeutics (AKTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Akari Therapeutics Q1 2025 $(0.00), Inline YoY

Akari Therapeutics (NASDAQ:AKTX) will report on Q1 2025.

Benzinga Newsdesk

PRO
Akari Therapeutics FY24 Net Loss From Operations $21.6M vs $16.8M YoY

Benzinga Newsdesk

PRO
Akari Therapeutics Q2 EPS $0.00

Benzinga Newsdesk

PRO
Akari Therapeutics As Of March 31, 2024, The Company Had Cash Of ~$1.3M

Benzinga Newsdesk

PRO
Akari Therapeutics' Cash Of Approximately $3.8M As of December 31, 2023. In March 2024, It Raised Approximately $2M Via Private Placement And Is Planning To Secure Additional Capital In Q2 Of 2024

Benzinga Newsdesk

PRO
Akari Therapeutics FY2023 EPS $0.00, Same YoY

Benzinga Newsdesk